Expanded Newborn Screening: Disclosures
Page Access:

    National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines Committee for Follow-Up Testing for Metabolic Diseases Identified by Expanded Newborn Screening Using Tandem Mass Spectrometry

These include all reported relationships within the previous 2 years that may be relevant to the guidelines document.

 

 

Grant

Other
Research Support

Speakers Bureau

Honoraria

Expert Witness

Ownership Interest

Consultant Advisory Board

Institution Employer

Other Disclosures

Bennett

Significant (>$10K)/Other

None

None

None

None

None

None

None

None

None

Rinaldo

Significant (>$10K)/Other

Not reported

Not reported

Not reported

Not reported

Not reported

Not reported

Not reported

Not reported

Not reported

Whitley

Significant (>$10K)/Other

None

None

None

None

None

None

None

None

None

Rhead

Significant (>$10K)/Other

Pfizer

None

None

None

None

None

None

None

None

Hannon

Significant (>$10K)/Other

None

 

None

None

None

None

None

None

None

None

Dietzen

Significant (>$10K)/Other

None

None

None

None

None

None

None

None

None

Garg

Significant (>$10K)/Other

None

None

None

None

None

None

None

None

None

Lo

Significant (>$10K)/Other

None

None

None

None

None

None

None

None

None